133 related articles for article (PubMed ID: 11778270)
1. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
4. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Zhou Z; Jia SF; Hung MC; Kleinerman ES
Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
Zhang Y; Yu D; Xia W; Hung MC
Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
[TBL] [Abstract][Full Text] [Related]
6. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
Chang JY; Xia W; Shao R; Hung MC
Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978
[TBL] [Abstract][Full Text] [Related]
8. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.
Zhou RR; Jia SF; Zhou Z; Wang Y; Bucana CD; Kleinerman ES
Cancer Gene Ther; 2002 May; 9(5):407-13. PubMed ID: 11961663
[TBL] [Abstract][Full Text] [Related]
10. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism.
Frisch SM; Dolter KE
Cancer Res; 1995 Dec; 55(23):5551-5. PubMed ID: 7585633
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
[TBL] [Abstract][Full Text] [Related]
14. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
Yu D; Shi D; Scanlon M; Hung MC
Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.
Yoo GH; Hung MC; Lopez-Berestein G; LaFollette S; Ensley JF; Carey M; Batson E; Reynolds TC; Murray JL
Clin Cancer Res; 2001 May; 7(5):1237-45. PubMed ID: 11350889
[TBL] [Abstract][Full Text] [Related]
16. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
17. SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu.
Wen CC; Cheng SA; Hsuen SP; Huang YL; Kuo ZK; Lee HF; Kuo CH; Du JL; Wang WB
Cancer Res; 2006 Jun; 66(11):5847-57. PubMed ID: 16740724
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth.
Zhang Y; Yang HY; Zhang XC; Yang H; Tsai M; Lee MH
Oncogene; 2004 Sep; 23(42):7132-43. PubMed ID: 15273726
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]